FDA Provides Notice on Agendia's Ongoing MammaPrint Recall
May 19, 2010
FDA Provides Notice on Agendia's Ongoing MammaPrint Recall
The FDA's April 21 notice said that over a period of about six months, approximately 15 percent of MammaPrint results over-reported the chance of metastasis risk as 29 percent risk of recurrence instead of 10 percent.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Faulty Reagent Caused 'Marginal' Over-Reporting of Breast Cancer Recurrence With MammaPrint
April 14, 2010 / Pharmacogenomics Reporter - Agendia to Offer FFPE Sample Analysis for Symphony Suite of Breast Cancer Diagnostics
December 21, 2011 / Pharmacogenomics Reporter - Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
August 11, 2010 / Pharmacogenomics Reporter - Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010 / Pharmacogenomics Reporter - New Releases
April 7, 2010 / Pharmacogenomics Reporter